399 related articles for article (PubMed ID: 17259345)
1. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
2. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of human ovarian carcinoma cell lines.
Yuan Y; Kim WH; Han HS; Lee JH; Park HS; Chung JK; Kang SB; Park JG
Gynecol Oncol; 1997 Sep; 66(3):378-87. PubMed ID: 9299249
[TBL] [Abstract][Full Text] [Related]
4. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
5. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
6. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.
Zhou C; Huang P; Liu J
Biochem Biophys Res Commun; 2005 Oct; 336(3):952-60. PubMed ID: 16165098
[TBL] [Abstract][Full Text] [Related]
7. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Aunoble B; Bernard-Gallon D; Bignon YJ
Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099
[TBL] [Abstract][Full Text] [Related]
8. Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1.
Fan S; Yuan R; Ma YX; Meng Q; Goldberg ID; Rosen EM
Oncogene; 2001 Dec; 20(57):8215-35. PubMed ID: 11781837
[TBL] [Abstract][Full Text] [Related]
9. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
Huper G; Marks JR
Cancer Res; 2007 Apr; 67(7):2990-3001. PubMed ID: 17409405
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
Husain A; He G; Venkatraman ES; Spriggs DR
Cancer Res; 1998 Mar; 58(6):1120-3. PubMed ID: 9515792
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Wang YQ; Zhang JR; Li SD; He YY; Yang YX; Liu XL; Wan XP
Cancer Sci; 2010 Jul; 101(7):1618-23. PubMed ID: 20487263
[TBL] [Abstract][Full Text] [Related]
12. [DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines].
Wang CY; Sun SK; Fu WJ; Song T; Cai W; Gao JP; Hong BF; Wang XX; Wang H
Zhonghua Nan Ke Xue; 2008 Aug; 14(8):685-9. PubMed ID: 18817338
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 regulation of transcription.
Rosen EM; Fan S; Ma Y
Cancer Lett; 2006 May; 236(2):175-85. PubMed ID: 15975711
[TBL] [Abstract][Full Text] [Related]
15. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
16. BCoR-L1 variation and breast cancer.
Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
[TBL] [Abstract][Full Text] [Related]
18. The roles of BRCA1 and BRCA2 in the cellular response to ionizing radiation.
Powell SN
Radiat Res; 2005 Jun; 163(6):699-700. PubMed ID: 16044500
[No Abstract] [Full Text] [Related]
19. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
Abramovitch S; Werner H
Horm Metab Res; 2003; 35(11-12):758-62. PubMed ID: 14710355
[TBL] [Abstract][Full Text] [Related]
20. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
